Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria

Emerg Infect Dis. 2022 Nov;28(11):2261-2269. doi: 10.3201/eid2811.220542.

Abstract

We sought to determine the prevalence of probable disseminated histoplasmosis among advanced HIV disease (AHD) patients in Nigeria. We conducted a cross-sectional study in 10 sites across 5 of 6 geopolitical zones in Nigeria. We identified patients with urinary samples containing CD4 cell counts <200 cells/mm3 or World Health Organization stage 3 or 4 disease who also had >2 clinical features of disseminated histoplasmosis, and we tested them for Histoplasma antigen using a Histoplasma enzyme immune assay. Of 988 participants we recruited, 76 (7.7%) were antigen-positive. The 76 Histoplasma antigen-positive participants had significantly lower (p = 0.03) CD4 counts; 9 (11.8%) were also co-infected with tuberculosis. Most antigen-positive participants (50/76; 65.8%; p = 0.015) had previously received antiretroviral treatment; 26/76 (34.2%) had not. Because histoplasmosis is often a hidden disease among AHD patients in Nigeria, Histoplasma antigen testing should be required in the AHD package of care.

Keywords: HIV/AIDS and other retroviruses; Nigeria; fungi; histoplasma; histoplasmosis; infections; respiratory infections; tuberculosis and other mycobacteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cross-Sectional Studies
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Histoplasma
  • Histoplasmosis* / diagnosis
  • Histoplasmosis* / drug therapy
  • Histoplasmosis* / epidemiology
  • Humans
  • Nigeria / epidemiology
  • Prevalence